Recombinant OC126 (Abagovomab Biosimilar) anticorps
Aperçu rapide pour Recombinant OC126 (Abagovomab Biosimilar) anticorps (ABIN7538052)
Antigène
Type d'anticorp
Reactivité
Hôte
Clonalité
Conjugué
Application
Classe de qualité
-
-
Expression System
- Mammalian cells
-
Fonction
- Abagovomab Biosimilar - Anti-idiotope of anti-Mus musculus monoclonal antibody OC126 mAb - Research Grade
-
Attributs du produit
- Antibody Type: idiotypic IgG1-kappa
-
Purification
- Recombinant antibody expressed in mammalien cells and purified.
-
Pureté
- > 85%
-
Isotype
- IgG1 kappa
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Buffer
- PBS buffer PH7.5
-
Stock
- -80 °C
-
Stockage commentaire
- store at -80°C
-
-
- OC126 (Abagovomab Biosimilar)
-
Classe de substances
- Biosimilar
-
Sujet
- Abagovomab is a murine monoclonal anti-idiotypic antibody (MW: 165-175 kDa), produced by a mouse hybridoma and generated against OC125, which serves to functionally imitate the human cancer antigen 125 (CA-125). Abagovomab has been developed by the pharmaceutical company Menarini for the treatment of ovarian cancer. It (ab2) shows high affinity for the paratope of ab1, and binding of ab2 to Ab1 is almost completely inhibited (93%) by the nominal antigen. The administration of F(ab')2 fragments of abagovomab to rats produces anti-CA-125 immunity with the production of IgG and IgM anti-anti-idiotypic antibodies (ab3) that bind both to abagovomab and CA-125. Non-MHC restricted cell-mediated cytotoxicity for NIH OVCAR3 cell lines is also demonstrated.
-
Numéro CAS
- 792921-10-9
Antigène
-